Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer
Open Access
- 1 September 2009
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 4 (9) , 1117-1125
- https://doi.org/10.1097/jto.0b013e3181b27b33
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407Journal of Clinical Oncology, 2011
- Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based studyAnnals of Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Definitive Chemoradiation for the Treatment of Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- A1-03: Rethinking prognostic factors in the era of combined modality therapy for Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC): a retrospective analysis of RTOG Protocols 9410 and 9801Journal of Thoracic Oncology, 2007
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006
- Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy GroupJournal of Clinical Oncology, 2006
- Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapyLung Cancer, 2006
- PD-48 Pemetrexed-based concurrent chemoradiotherapy (CRT)for locally advanced or metastatic non-small cell lung or esophageal cancer: A phase I dose-escalating studyLung Cancer, 2005
- Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicityAnnals of Oncology, 2004